NFL AS A POSSIBLE BIOMARKER OF TREATMENT RESPONSE IN HEREDITARY ATTR AMYLOIDOSIS: DATA FROM THE PATISIRAN APOLLO OLE STUDY

被引：0
|
作者：
Sekijima, Y. [1 ]
Polydefkis, M. [2 ]
Ticau, S. [3 ]
Erbe, D. [3 ]
McManus, A. [3 ]
Aldinc, E. [3 ]
Adams, D. [4 ]
Reilly, M. M. [5 ]
Vaishnaw, A. [3 ]
Nioi, P. [3 ]
机构：
[1] Shinshu Univ Sch Med, Dept Med Neurol & Rheumatol, Nagano, Japan
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Alnylam Pharmaceut, Cambridge, MA USA
[4] Univ Paris Saclay, APHP, CHU Bicetre, INSERM, Le Kremlin Bicetre, France
[5] UCL Queen Sq Inst Neurol, MRC Ctr Neuromuscular Dis, London, England
来源：
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM | 2022年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S12 / S13
页数：2
相关论文
共 50 条
  • [21] Effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis: insights from pressure-volume analysis of the APOLLO study
    Rosenblum, Hannah R.
    Griffin, Jan M.
    Minamisawa, Masatoshi
    Prasad, Narayana
    Vest, John
    White, Matthew T.
    Solomon, Scott D.
    Burkhoff, Daniel
    Maurer, Mathew S.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (05) : 727 - 736
  • [22] EFFECTS OF PATISIRAN, AN RNA INTERFERENCE THERAPEUTIC, ON REGIONAL LEFT VENTRICULAR MYOCARDIAL DEFORMATION IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS: THE APOLLO STUDY
    Minamisawa, Masatoshi
    Adams, David
    Kristen, Arnt
    Merlini, Giampaolo
    Slama, Michel S.
    Dispenzieri, Angela
    Falk, Rodney H.
    Karsten, Verena
    Sweetser, Marianne
    Chen, Jihong
    Riese, Richard
    Vest, John
    Solomon, Scott
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 816 - 816
  • [23] Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis The APOLLO Study
    Minamisawa, Masatoshi
    Claggett, Brian
    Adams, David
    Kristen, Arnt V.
    Merlini, Giampaolo
    Slama, Michel S.
    Dispenzieri, Angela
    Shah, Amil M.
    Falk, Rodney H.
    Karsten, Verena
    Sweetser, Marianne T.
    Chen, Jihong
    Riese, Richard
    Vest, John
    Solomon, Scott D.
    JAMA CARDIOLOGY, 2019, 4 (05) : 466 - 472
  • [24] Patisiran, an Investigational RNAi Therapeutic for Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy: Results from the Phase 3 APOLLO study
    Adams, David
    Gonzalez-Duarte, Alejandra
    O'Riordan, William
    Yang, Chih-Chao
    Yamashita, Taro
    Kristen, Arnt
    Tournev, Ivaylo
    Schmidt, Hartmut
    Coelho, Teresa
    Berk, John L.
    Lin, Kon-Ping
    Dyck, Peter J.
    Gandhi, Pritesh
    Sweetser, Marianne
    Chen, Jihong
    Goyal, Sunita
    Gollob, Jared
    Suhr, Ole
    NEUROLOGY, 2018, 90
  • [25] Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study
    Solomon, Scott D.
    Adams, David
    Kristen, Arnt
    Grogan, Martha
    Gonzalez-Duarte, Alejandra
    Maurer, Mathew S.
    Merlini, Giampaolo
    Damy, Thibaud
    Slama, Michel S.
    Brannagan, Thomas H., III
    Dispenzieri, Angela
    Berk, John L.
    Shah, Amil M.
    Garg, Pushkal
    Vaishnaw, Akshay
    Karsten, Verena
    Chen, Jihong
    Gollob, Jared
    Vest, John
    Suhr, Ole
    CIRCULATION, 2019, 139 (04) : 431 - 443
  • [26] PATISIRAN STABILIZES CARDIAC MECHANICS IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS: POST-HOC ANALYSIS OF THE APOLLO STUDY
    Rosenblum, Hannah
    Griffin, Jan
    Minamisawa, Masatoshi
    Prasad, Narayana
    Vest, John
    White, Matthew
    Solomon, Scott
    Burkhoff, Daniel
    Maurer, Mathew
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 524 - 524
  • [27] Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis
    Zhang, Xiaoping
    Goel, Varun
    Attarwala, Husain
    Sweetser, Marianne T.
    Clausen, Valerie A.
    Robbie, Gabriel J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (01): : 37 - 49
  • [28] Phase 2 open-label extension study of patisiran, an investigational siRNA agent for hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN)
    Conceicao, I.
    Suhr, O.
    Coelho, T.
    Cruz, M. Waddington
    Schmidt, H.
    Buades, J.
    Campistol, J.
    Pouget, J.
    Berk, I.
    Adams, D.
    NEUROMUSCULAR DISORDERS, 2016, 26 : S142 - S142
  • [29] Impact of prior TTR stabilizer use in patients with hereditary Transthyretin-Mediated Amyloidosis in the APOLLO phase-3 study of Patisiran
    Coelho, T.
    Adams, D.
    Gonzalez-Duarte, A.
    O'Riordan, W.
    Yang, C-C.
    Yamashita, T.
    Kristen, A.
    Tournev, I.
    Schmidt, H.
    Berk, J.
    Lin, K-P.
    Gandhi, P.
    Sweetser, M.
    Chen, J.
    Goyal, S.
    Gollob, J.
    Suhr, O.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 17 - 18
  • [30] Response by Solomon to Letter Regarding Article, "Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study"
    Solomon, Scott D.
    CIRCULATION, 2019, 140 (02) : E92 - E93
12345